Making Sense From Anti-Sense: Lessons In Translating Expedited Regulatory Approval Into Reimbursement And Commercial Success

October 4, 2018 Danielle Twigg

Emerging new therapy classes (e.g. CAR-T and gene therapies) with potential curative benefits across severe and rare diseases are likely candidates for expedited regulatory approval but their high prices will incur strong payer scrutiny. Previous innovative therapy classes can provide valuable insights in this regard. Oligonucleotide therapies (antisense oligonucleotides
(ASOs), morpholinos, aptamers, and siRNAs) can target and modify transcripts of specific disease-causing genes. This research evaluates their regulatory, reimbursement and commercial success.

Authors: Bebee T1, Macaulay R2
1PAREXEL International, Horsham, PA, USA, 2PAREXEL International, London, United Kingdom

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets
A Comparison Of P&R Requirements For Orphan Drugs In 25 Markets

Next Article
How Classification Of Cell And Gene Therapies As Drugs, Devices Or Procedures Could Have Significant Implications
How Classification Of Cell And Gene Therapies As Drugs, Devices Or Procedures Could Have Significant Implications